Comparison of Reproductive Outcomes on addition of GnRH agonist for Luteal phase Support in Antagonist IVF cycle | ||||
| The Egyptian Journal of Fertility of Sterility | ||||
| Article 6, Volume 25, Issue 3, September 2021, Page 55-64 PDF (2.27 MB) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/egyfs.2021.195179 | ||||
 View on SCiNiTO | ||||
| Author | ||||
| LUKMAN OMOTAYO OMOKANYE | ||||
| DEPARTMENT OF OBSTETRICS AND GYNAECOLOGY, FACULTY OF HEALTH SCIENCES, UNIVERSITY OF ILORIN, KWARA STATE, NIGERIA | ||||
| Abstract | ||||
| Background: The luteal phase supplementation was reported to be necessary in Controlled Ovarian Hyperstimulation cycles for IVF or ICSI, independently when agonists or antagonist were used for pituitary desensitization. The effectiveness of GnRH agonist in luteal phase supplementation remains controversial. Aims and Objectives: This study aimed at comparing the clinical outcomes of addition of GnRH agonist for luteal phase support in antagonist IVF cycle. Materials and Methods: A cross-sectional study of 150 eligible clients who underwent assisted reproduction program in two autonomous IVF centers between 1st January, 2017 and 31st December, 2020. Clients were divided into two groups; (I) Antagonist stimulation protocol with progesterone and oestradiol valerate and (II) Antagonist Protocol with a single bolus of buserelin in addition to progesterone and oestradiol valerate for luteal phase support. The primary outcome was live birth rates while the secondary outcomes were clinical pregnancy, miscarriage rates and the safety for OHSS. Results: There were no statistically significant differences between the number of oocyte received, fertilized, embryos availability for transfer, duration of infertility, duration of FSH usage, endometrial thickness and OHSS risk between the groups (p>0.05). The clinical pregnancy and live birth rates were more in group II while the miscarriage rate was lower compared to group I. The differences were statistically significant (p < 0.005). Conclusion: From this study, buserelin addition to the luteal phase of antagonist cycles appears to improve pregnancy outcomes with no associated increase in OHSS risk. Further multi- centered studies with larger sample sizes are required to validate these findings. | ||||
| Keywords | ||||
| Keywords: Comparison; Antagonist protocol; GnRH- agonist; luteal phase | ||||
|
Statistics Article View: 132 PDF Download: 207 |
||||
